Axon Enterprise (NASDAQ:AXON) Price Target Raised to $600.00

Axon Enterprise (NASDAQ:AXON) had its target price hoisted by stock analysts at UBS Group from $440.00 to $600.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. UBS Group’s target price suggests a potential upside of 14.09% from the stock’s current price.

A number of other equities research analysts also recently issued reports on AXON. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, July 21st. TD Cowen restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, July 22nd. Weiss Ratings raised Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $715.00 price objective on shares of Axon Enterprise in a research note on Thursday. Finally, Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 10th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $730.92.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON traded down $83.58 during trading on Thursday, hitting $525.91. 1,433,543 shares of the company’s stock were exchanged, compared to its average volume of 1,070,147. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. Axon Enterprise has a 52-week low of $339.01 and a 52-week high of $885.00. The business’s 50-day simple moving average is $509.69 and its 200 day simple moving average is $474.71. The company has a market cap of $42.39 billion, a price-to-earnings ratio of 208.37, a PEG ratio of 12.39 and a beta of 1.39.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. The firm had revenue of $904.39 million during the quarter, compared to analyst estimates of $876.42 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. Axon Enterprise’s revenue for the quarter was up 35.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.12 earnings per share. As a group, equities analysts predict that Axon Enterprise will post 1.63 EPS for the current year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $643.79, for a total transaction of $6,437,900.00. Following the sale, the chief executive officer directly owned 3,040,997 shares in the company, valued at approximately $1,957,763,458.63. The trade was a 0.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Caitlin Elizabeth Kalinowski sold 564 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $478.97, for a total transaction of $270,139.08. Following the completion of the transaction, the director owned 3,632 shares of the company’s stock, valued at $1,739,619.04. This trade represents a 13.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 58,989 shares of company stock worth $30,527,983 in the last three months. Insiders own 4.20% of the company’s stock.

Institutional Trading of Axon Enterprise

Several institutional investors have recently made changes to their positions in the stock. Baillie Gifford & Co. grew its position in Axon Enterprise by 1,198.7% during the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after purchasing an additional 1,516,099 shares in the last quarter. Edgewood Management LLC purchased a new stake in Axon Enterprise in the 4th quarter worth approximately $846,516,000. Wellington Management Group LLP boosted its stake in shares of Axon Enterprise by 326.9% during the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after buying an additional 1,179,038 shares during the period. Norges Bank acquired a new stake in shares of Axon Enterprise during the 4th quarter valued at $515,764,000. Finally, Styrax Capital LP purchased a new position in shares of Axon Enterprise during the 1st quarter valued at $84,938,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon reported second-quarter revenue of $904 million, up 35.3% year over year and ahead of Wall Street expectations. Non-GAAP earnings reached $1.88 per share, roughly in line with or slightly above consensus estimates. Axon reports Q2 2026 revenue of $904 million, up 35% year over year
• Positive Sentiment: Management raised its full-year 2026 revenue-growth outlook to 32%-34% while maintaining its 25.5% adjusted EBITDA margin target. Annual recurring revenue increased 39% to $1.6 billion, with net revenue retention at 126%.
• Positive Sentiment: Growth remains broad-based: Software & Services revenue rose 36%, AI Era revenue nearly quadrupled year over year, Platform Solutions revenue increased 123%, and Dedrone revenue surpassed $100 million. Record bookings, international expansion and counter-drone demand supported the upbeat outlook. Axon Q2 earnings call highlights
• Neutral Sentiment: William Blair analyst Jonathan Ho reiterated a Buy rating, citing recurring-revenue growth, the expanding AI platform and momentum in counter-drone products. Axon receives a fresh Buy rating
• Negative Sentiment: Gross margin weakened, particularly in Software & Services, falling to 71.3% from 75.6% as professional services and newer product investments carried lower margins. Higher memory costs are expected to create additional near-term pressure. Axon posts lower quarterly gross margin
• Negative Sentiment: Free cash flow turned negative and net income declined from the prior-year period, while inventory increased. These trends raised concerns that rapid expansion is requiring heavier investment than expected.
• Negative Sentiment: At a valuation above 200 times earnings, Axon remains vulnerable to multiple compression. Some valuation analysis indicates the stock looks expensive on a discounted-cash-flow basis, making profitability and cash-flow execution especially important for investors.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.